Alliance Global lowered the firm's price target on Acurx to $10 from $20 and keeps a Buy rating on the shares following the Q4 report. The firm pushed back its expected FDA approval of ibezapolstat for C. difficile infection to 2031 from 2028, but says the new open label Phase 2 "will afford the opportunity for additional data quicker and cheaper."
